CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Overview
USA - NASDAQ:CNTB - US2075231017 - Common Stock
CNTB Key Statistics, Chart & Performance
The current stock price of CNTB is 1.61 USD. In the past month the price decreased by -11.05%. In the past year, price increased by 30.89%.
CNTB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.85 | 390.07B | ||
| AMGN | AMGEN INC | 12.6 | 147.89B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 139.29B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.85 | 99.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 62.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.21B | ||
| ARGX | ARGENX SE - ADR | 79.22 | 44.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.8 | 39.49B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.08B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.59B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About CNTB
Company Profile
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Company Info
CONNECT BIOPHARMA HOLDINGS L
3580 Carmel Mountain Road, Suite 200
San Diego CALIFORNIA 215400 US
CEO: William Pan
Employees: 62
Phone: 18587271040
CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ
What is the stock price of CONNECT BIOPHARMA HOLDINGS L today?
The current stock price of CNTB is 1.61 USD.
What is the ticker symbol for CONNECT BIOPHARMA HOLDINGS L stock?
The exchange symbol of CONNECT BIOPHARMA HOLDINGS L is CNTB and it is listed on the Nasdaq exchange.
On which exchange is CNTB stock listed?
CNTB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CONNECT BIOPHARMA HOLDINGS L stock?
9 analysts have analysed CNTB and the average price target is 6.97 USD. This implies a price increase of 332.92% is expected in the next year compared to the current price of 1.61. Check the CONNECT BIOPHARMA HOLDINGS L stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CONNECT BIOPHARMA HOLDINGS L worth?
CONNECT BIOPHARMA HOLDINGS L (CNTB) has a market capitalization of 89.71M USD. This makes CNTB a Micro Cap stock.
How many employees does CONNECT BIOPHARMA HOLDINGS L have?
CONNECT BIOPHARMA HOLDINGS L (CNTB) currently has 62 employees.
What are the support and resistance levels for CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
CONNECT BIOPHARMA HOLDINGS L (CNTB) has a support level at 1.59 and a resistance level at 1.9. Check the full technical report for a detailed analysis of CNTB support and resistance levels.
Is CONNECT BIOPHARMA HOLDINGS L (CNTB) expected to grow?
The Revenue of CONNECT BIOPHARMA HOLDINGS L (CNTB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CNTB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNTB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNTB, evaluating the profitability, health, valuation and growth aspects
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Sales and EPS estimates to see what analysts future expectations are.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Insider and Institutional Ownership to learn about the owners and their transactions.
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Chart to make your own analysis
- CONNECT BIOPHARMA HOLDINGS L (CNTB) Latest news and press-releases to stay up to date.
Does CONNECT BIOPHARMA HOLDINGS L (CNTB) stock pay dividends?
CNTB does not pay a dividend.
What is the Price/Earnings (PE) ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB)?
CONNECT BIOPHARMA HOLDINGS L (CNTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
What is the Short Interest ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
The outstanding short interest for CONNECT BIOPHARMA HOLDINGS L (CNTB) is 0.09% of its float. Check the ownership tab for more information on the CNTB short interest.
CNTB Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CNTB. When comparing the yearly performance of all stocks, CNTB is one of the better performing stocks in the market, outperforming 89.78% of all stocks.
CNTB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNTB. CNTB has a great financial health rating, but its profitability evaluates not so good.
CNTB Financial Highlights
Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 47.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.88% | ||
| ROE | -8.66% | ||
| Debt/Equity | 0 |
CNTB Forecast & Estimates
9 analysts have analysed CNTB and the average price target is 6.97 USD. This implies a price increase of 332.92% is expected in the next year compared to the current price of 1.61.
For the next year, analysts expect an EPS growth of -328.29% and a revenue growth -100% for CNTB